SCHEMBL9849401

SCHEMBL9849401

NC(=O)c1cc2ccccc2n(O)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.50
KDM4E B2RXH2 5/20 0.47
IRAK4 Q9NWZ3 1/20 0.44
IKBKB O14920 1/20 0.44
GAA P10253 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPK1 P28482 1/20 0.42
AHR P35869 3/20 0.40
PLA2G10 O15496 1/20 0.39
SLC9A1 P19634 1/20 0.39
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
PABPC1 P11940 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MCL1 Q07820 1/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9849536 0.84 DAO (0.61) DAOKDM4EALDH1A1AHRMAPT
SCHEMBL11983168 0.81 DAO (0.60) DAOKDM4EIRAK4IKBKBALDH1A1
SCHEMBL29932906 0.81 DAO (0.60) DAOKDM4EIRAK4IKBKBALDH1A1
SCHEMBL10671761 0.79 ALDH1A1 (0.54) DAOKDM4EALDH1A1AHRMAPT
SCHEMBL30337559 0.78 HTR4 (0.56) IRAK4
SCHEMBL6547150 0.78 MAPK1 (0.47) KDM4EIRAK4ALDH1A1MAPK1PLA2G10
SCHEMBL7670332 0.77 DAO (0.70) DAOALDH1A1PLA2G10SLC9A1MCL1
SCHEMBL16236070 0.75 KDM4E (0.59) KDM4EGAAALDH1A1MAPTMEN1
SCHEMBL9849390 0.75 IRAK4 (0.44) DAOKDM4EIRAK4IKBKBGAA
SCHEMBL16237012 0.74 PARP1 (0.47) DAOKDM4EIRAK4IKBKBAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109415360-A Compounds and compositions for inhibiting SHP2 activity 诺华股份有限公司 2019-03-01 CN disclosed
US-10208035-B2 Compounds for inhibiting drug-resistant strains of HIV-1 integrase THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2019-02-19 US disclosed
US-20170305904-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) 2017-10-26 US disclosed
US-9676771-B2 Compounds for inhibiting drug-resistant strains of HIV-1 integrase THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2017-06-13 US disclosed
US-20160083382-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE The United States of American, as represented by the Sec, Dept. of Health and Human Services (US) 2016-03-24 US disclosed
EP-0446604-A2 Pyridine and related aza heterocycle derivatives as cardiovascular agents AMERICAN CYANAMID COMPANY (US) 1991-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10208035-B2 Compounds for inhibiting drug-resistant strains of HIV-1 integrase CCR8, CDK8, CHD8 DAO 1147/4885KDM4E 1233/4885IRAK4 1657/4885
US-20170305904-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE CCR8, CDK8, CHD8 DAO 1147/4885KDM4E 1233/4885IRAK4 1657/4885
US-20160083382-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE CCR8, CDK8, CHD8 DAO 1147/4885KDM4E 1233/4885IRAK4 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.